Copyright
©The Author(s) 2022.
World J Clin Cases. Oct 6, 2022; 10(28): 10085-10096
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10085
Published online Oct 6, 2022. doi: 10.12998/wjcc.v10.i28.10085
Table 1 Hepatitis B virus DNA levels in chronic hepatitis B patients at weeks 168 and 192 (mean SD, log10IU/mL)
| Group | HBeAg-positive | HBeAg-negative | ||||
| Baseline | 168 wk | 192 wk | Baseline | 168 wk | 192 wk | |
| A | 7.64 ± 1.01 | 1.18 ± 0.86 | 0.9 ± 0.96 | 6.22 ± 1.25 | 0.62 ± 0.66 | 0.35 ± 0.59 |
| B | 7.65 ± 0.95 | 1.13 ± 0.82 | 1.02 ± 0.85 | 6.31 ± 1.37 | 0.36 ± 0.61 | 0.33 ± 0.57 |
| P | 0.937 | 0.728 | 0.560 | 0.798 | 0.150 | 0.867 |
- Citation: Xu JH, Wang S, Zhang DZ, Yu YY, Si CW, Zeng Z, Xu ZN, Li J, Mao Q, Tang H, Sheng JF, Chen XY, Ning Q, Shi GF, Xie Q, Zhang XQ, Dai J. One hundred and ninety-two weeks treatment of entecavir maleate for Chinese chronic hepatitis B predominantly genotyped B or C. World J Clin Cases 2022; 10(28): 10085-10096
- URL: https://www.wjgnet.com/2307-8960/full/v10/i28/10085.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i28.10085